arrow_back Trending Legislation
Share share

Limiting FDA Funds for Fiscal Year 2024

This bill proposes to cap the spending for the Food and Drug Administration (FDA) for the 2024 fiscal year. This means the FDA will have less money available for its operations, potentially affecting the speed of new drug approvals, food safety, or scientific research. Citizens might experience this through longer waits for new treatments or changes in oversight of food products.
Key points
The bill sets a maximum spending limit for the Food and Drug Administration (FDA) for 2024 at approximately $5.58 billion.
This budget limitation for the FDA could impact its ability to conduct research, inspections, and product approvals, potentially affecting drug availability and food safety.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
To provide for a limitation on availability of funds for Related Agency and Food and Drug Administration, Department of Health and Human Services, Food and Drug Administration, for fiscal year 2024.
Print number: HR 2295
Sponsor: Rep. Biggs, Andy [R-AZ-5]
Process start date: 2023-03-29
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Limiting FDA Funds for Fiscal Year 2024

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is HR 2295.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-03-29.

What are the main provisions?

Key points include:

  • The bill sets a maximum spending limit for the Food and Drug Administration (FDA) for 2024 at approximately $5.58 billion.
  • This budget limitation for the FDA could impact its ability to conduct research, inspections, and product approvals, potentially affecting drug availability and food safety.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Biggs, Andy [R-AZ-5].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-24.

Analysis and Potential Impact of HR 2295

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health